Elegen's ENFINIA Linear DNA Revolutionizes Synthetic Biology
Elegen Corporation has introduced ENFINIA Linear DNA, a revolutionary product set to transform synthetic biology, protein engineering, and drug discovery. This linear DNA synthesis product promises to streamline workflows and enhance protein screening capabilities.
ENFINIA Linear DNA stands out by eliminating the need for traditional cloning or PCR amplification steps, significantly reducing hands-on time and enabling higher-throughput protein screening. This innovation addresses bottlenecks in traditional DNA template synthesis, improving TXTL screening efficiency.
In GeneFrontier's PUREfrex system, ENFINIA Linear DNA demonstrates superior performance in terms of DNA purity, transcription efficiency, and robust protein expression. Moreover, it can tackle challenging protein sequences such as long repeats, GC-rich promoters, and homopolymers, expanding its applicability.
Elegen Corporation's ENFINIA Linear DNA, produced using proprietary cell-free DNA production technology, offers a high-accuracy, NGS-verified solution. By simplifying workflows and enhancing screening capabilities, it has the potential to accelerate advancements in synthetic biology, protein engineering, and drug discovery.
Read also:
- Minimal Essential Synthetic Intelligences Enterprise: Essential Minimum Agents
- Tesla is reportedly staying away from the solid-state battery trend, as suggested by indications from CATL and Panasonic.
- UK automaker, Jaguar Land Rover, to commit £500 million for electric vehicle manufacturing in Merseyside
- Standard Nuclear & Framatome Join Forces to Boost TRISO Fuel Production by 2027
